Global Tinea Versicolor treatment Market Size, Share, Forecast Report, 2020-2027

Tinea Versicolor is one of the common types of skin infection. It also called as pityriasis versicolor. In this condition, small and discolored patches of skin occur, mostly affecting the shoulders and trunk.

Increasing prevalence of tinea versicolor, increasing awareness of the disease, rising healthcare expenditure, advanced diagnosis and treatment options, and approval of new antifungal medicines are leading the growth of global tinea versicolor treatment market.

Global tinea versicolor treatment market is expected to grow at the CAGR of ~7.1% during the forecast period and is estimated to reach USD 197.9 million by 2023.
Segments:

Global tinea versicolor treatment market has been segmented on the basis of diagnosis which comprise physical exam, imaging tests, and others. Imaging test is sub-segmented into wood lamp (black light) examination, microscopy using potassium hydroxide (KOH), fungal culture, skin biopsy, and others. Skin biopsy is sub-segmented into shave biopsy, punch biopsy, excisional biopsy, and others.

On the basis of treatments, the market has been segmented into antifungal shampoos, antifungal creams, drugs, and others. Antifungal shampoos are sub-segmented into selenium sulfide (selsun) 2.5 percent shampoo, ciclopirox (loprox, penlac) shampoo, ketoconazole (ketoconazole, nizoral, others) shampoo, and others. Antifungal creams are sub-segmented into Selenium sulfide (Selsun) 2.5 percent lotion, Ciclopirox (Loprox, Penlac) cream or gel, Ketoconazole (Ketoconazole, Nizoral, others) cream or gel, and others. Drugs are further sub-segmented into fluconazole (diflucan) tablets or oral solution, and others.

On the basis of end user, it is segmented into dermatology hospital and clinics, medical research centers, academic institutes, and others.
Key players for global Tinea Versicolor treatment market:

Some of the key players in this market are: Astellas Pharma US, Inc. (Japan), Bayer AG (German), Enzon Pharmaceuticals, Inc. (US), Galderma S.A. (Switzerland), Gilead (US), Novartis AG (Switzerland), Pfizer Inc. (US), Taro Pharmaceutical Industries Ltd. (US), Teva Pharmaceutical Industries Ltd. (Israel), Valeant (Canada), and others.